Anti-CD18 monoclonal antibody
Alternative Names: Anti-CD18; IB4Latest Information Update: 31 Mar 2022
Price :
$50 *
At a glance
- Originator Pharmacia Corporation
- Developer Pharmacia Corporation; Sanofi; Seikagaku America
- Class
- Mechanism of Action Immunosuppressants; Lymphocyte function-associated antigen-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction; Stroke; Transplant rejection
Most Recent Events
- 24 Jan 2001 No-Development-Reported for Myocardial infarction in United Kingdom (Unknown route)
- 24 Jan 2001 No-Development-Reported for Myocardial infarction in USA (Unknown route)
- 24 Jan 2001 No-Development-Reported for Stroke in USA (Unknown route)